By Lynda Williams, medwireNews Reporter
medwireNews: For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © Giama22 / Generated with AI / Stock.adobe.com
